hydrocodone bitartrate

FDA Drug Profile — Hysingla ER

hydrocodone bitartrate is listed in the FDA National Drug Code directory with 6 NDC codes, marketed under brand name including Hysingla ER. Available dosage form: tablet, extended release.

Drug details

Generic Name
hydrocodone bitartrate
Brand Names
Hysingla ER
Application Number
NDA206627
Sponsor
Knoa Pharma LLC
NDC Codes
6
Dosage Forms
TABLET, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
HYDROCODONE BITARTRATE

Indications and Usage

1 INDICATIONS AND USAGE HYSINGLA ER is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including HYSINGLA ER, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. HYSINGLA ER is not indicated as an as-needed (prn) analgesic. HYSINGLA ER is an opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including HYSINGLA ER, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) HYSINGLA ER is not indicated as an as-needed (prn) analgesic. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.